Pharmaceutical Statistics

Table of Contents

Pharmaceutical Statistics - Early View Articles

${pageCtx.sharedData.issuePages}

MAIN PAPERS

From waterfall plots to spaghetti plots in early oncology clinical development

  • Author: Francois Mercier, Nicola Consalvo, Nicolas Frey, Alex Phipps, Benjamin Ribba
  • Pub Online: Apr 03, 2019
  • DOI: 10.1002/pst.1944 (p )

Assessing noninferiority: Evaluating efficacy of a new treatment without complete data

  • Author: Ping Gao, Katherine Odem‐Davis
  • Pub Online: Apr 12, 2019
  • DOI: 10.1002/pst.1946 (p )

Equilibrium, affinity, dissociation constants, IC5O: Facts and fantasies

  • Author: Jacques Barbet, Sandrine Huclier‐Markai
  • Pub Online: Apr 12, 2019
  • DOI: 10.1002/pst.1943 (p )

A flexible parametric survival model for fitting time to event data in clinical trials

  • Author: Jason J.Z. Liao, Guanghan Frank Liu
  • Pub Online: Apr 29, 2019
  • DOI: 10.1002/pst.1947 (p )

Choosing between the BP and BN sequential strategies

  • Author: Donna K. McClish, Amber R. Wilk, Christine M. Schubert
  • Pub Online: May 08, 2019
  • DOI: 10.1002/pst.1945 (p )

Controlling for confounding via propensity score methods can result in biased estimation of the conditional AUC: A simulation study

  • Author: Hadiza I. Galadima, Donna K. McClish
  • Pub Online: May 20, 2019
  • DOI: 10.1002/pst.1948 (p )

Viewpoints

MAIN PAPERS

Detecting bliss synergy in in vivo combination studies with a tumor kinetic model

  • Author: Wei Zhao, Paolo Vicini, Steven Novick, Judith Anderton, Gareth Davies, Gina DAngelo, Terrance O'Day, Binbing Yu, Jay Harper, Rajesh Narwal, Lorin Roskos, Harry Yang
  • Pub Online: May 29, 2019
  • DOI: 10.1002/pst.1952 (p )

Book Reviews

MAIN PAPERS

Controlling type I error in the reference‐scaled bioequivalence evaluation of highly variable drugs

  • Author: Jordi Ocaña, Joel Muñoz
  • Pub Online: Jun 12, 2019
  • DOI: 10.1002/pst.1950 (p )

TEACHERS' CORNER

Between a ROC and a hard place: Teaching prevalence plots to understand real world biomarker performance in the clinic

  • Author: B. Clare Lendrem, Dennis W. Lendrem, Arthur G. Pratt, Najib Naamane, Peter McMeekin, Wan‐Fai Ng, A. Joy Allen, Michael Power, John Dudley Isaacs
  • Pub Online: Jun 23, 2019
  • DOI: 10.1002/pst.1963 (p )

MAIN PAPERS

Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method

  • Author: Lingyun Ji, Juan Pablo Lewinger, Mark Krailo, Susan Groshen, David V. Conti, Shahab Asgharzadeh, Richard Sposto
  • Pub Online: Jun 25, 2019
  • DOI: 10.1002/pst.1955 (p )

A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations

  • Author: Cynthia Huber, Norbert Benda, Tim Friede
  • Pub Online: Jul 03, 2019
  • DOI: 10.1002/pst.1951 (p )

Random effects models for estimation of the probability and time to progression of a continuous biomarker

  • Author: Tarylee Reddy, Geert Molenberghs, Liesbeth Bruckers, Edmund‐Njeru Njagi, Marc Aerts, Geert Willem Schurink
  • Pub Online: Jul 15, 2019
  • DOI: 10.1002/pst.1956 (p )
Page:   1 2 3 Next

Related Topics

Related Publications

Related Content

Site Footer

Address:

This website is provided by John Wiley & Sons Limited, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ (Company No: 00641132, VAT No: 376766987)

Published features on StatisticsViews.com are checked for statistical accuracy by a panel from the European Network for Business and Industrial Statistics (ENBIS)   to whom Wiley and StatisticsViews.com express their gratitude. This panel are: Ron Kenett, David Steinberg, Shirley Coleman, Irena Ograjenšek, Fabrizio Ruggeri, Rainer Göb, Philippe Castagliola, Xavier Tort-Martorell, Bart De Ketelaere, Antonio Pievatolo, Martina Vandebroek, Lance Mitchell, Gilbert Saporta, Helmut Waldl and Stelios Psarakis.